Eden Mahdavi

Eden Mahdavi

Auto-generated profile, based on publicly available information

Eden Mahdavi

Octant, Inc

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2025 in bioRxiv
Verified
Preprint
Open access
CHConor J. Howard
Conor J. Howard
NANathan S. Abell
Nathan S. Abell
RWRobert R. Warneford-Thomson
Robert R. Warneford-Thomson
EMEden Mahdavi
Eden Mahdavi
ASAlan L. Su
Alan L. Su
DDDiane E. Dickel
Diane E. Dickel
Tyrosine Kinase 2 (TYK2) is a genetically defined target for autoimmune disease, with first-generation inhibitors showing clinical success in some but not all associated indications. A deeper understanding of TYK2 structure-function, protein-ligand interactions, and the impact of human variants could inform next-generation therapeutics. Here, we applied Deep Mutational Scanning (DMS) to assess >23,000 amino acid substitutions across two TYK2 functions: IFN-α signaling and protein abundance. This enabled high-resolution structure-function mapping and the identification of novel allosteric sites. By coupling DMS with inhibitor treatment, we uncovered variants that modulate compound potency. We also show that human variants – both common and rare – that are protective against autoimmune phenotypes reduce TYK2 protein abundance. Together, these findings demonstrate that DMS can prospectively reveal novel druggable sites, clarify structure-activity relationships (SAR), and highlight TYK2 degradation as a potential therapeutic strategy in autoimmunity.

4 March 2026 in eLife preprints
Verified
Preprint
Open access
PDF file
CHConor J Howard
Conor J Howard
NANathan S Abell
Nathan S Abell
RWRobert R Warneford-Thomson
Robert R Warneford-Thomson
EMEden Mahdavi
Eden Mahdavi
ASAlan L Su
Alan L Su
DDDiane E Dickel
Diane E Dickel
Tyrosine Kinase 2 (TYK2) is a genetically defined target for autoimmune disease, with first-generation inhibitors showing clinical success in some but not all associated indications. A deeper understanding of TYK2 structure-function, protein-ligand interactions, and the impact of human variants could inform next-generation therapeutics. Here, we applied Deep Mutational Scanning (DMS) to assess >23,000 amino acid substitutions across two TYK2 functions: IFN-α signaling and protein abundance. This enabled high-resolution structure-function mapping and the identification of novel allosteric sites. By coupling DMS with inhibitor treatment, we uncovered variants that modulate compound potency. We also show that human variants – both common and rare – that are protective against autoimmune phenotypes reduce TYK2 protein abundance. Together, these findings demonstrate that DMS can prospectively reveal novel druggable sites, clarify structure-activity relationships (SAR), and highlight TYK2 degradation as a potential therapeutic strategy in autoimmunity.